Nephron-sparing surgery for small incidental renal cell carcinoma
โ Scribed by Mark Sullivan; Mark Frydenberg
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 394 KB
- Volume
- 71
- Category
- Article
- ISSN
- 1445-1433
No coin nor oath required. For personal study only.
โฆ Synopsis
Background: Nephronโsparing surgery is currently an accepted treatment for renal cell carcinomas in patients with bilateral tumours, solitary kidneys and when overall renal function is impaired or at risk from medical disease. Its role in patients with a normal contralateral kidney remains controversial.
Methods: The authorsโ experience in 23 patients undergoing partial nephrectomy for small peripheral lesions between 1995 and 2000 is reported here.
Results: Twentyโthree patients (13 men and 10 women) with a mean age of 56 years underwent partial nephrectomy. All but three of these patients had a normal contralateral kidney. Mean operating time was 141 min with a mean reduction of haemoglobin of 28 g/dL. Three patients required transfusion. Serum creatinine did not change significantly between preoperative and postoperative values. Two JJ stents were placed prophylactically during surgery to minimize urinary leak. There were no intraoperative or early postoperative deaths and at mean follow up of 16 months there was no evidence of recurrent tumour in 23 patients. Seventeen per cent of lesions removed were benign.
Conclusions: Partial nephrectomy for small peripheral lesions is a safe procedure with low morbidity. No definite recurrences are evident at an early stage of follow up, although longer review (probably more than 10 years) will be required to assess cancerโspecific survival following this procedure.
๐ SIMILAR VOLUMES
## Abstract ## BACKGROUND. The role of nephronโsparing surgery (NSS) showed promise in patients with metastatic renal cell carcinoma (MRCC). The diseaseโspecific survival of patients with MRCC was compared according to the type of surgery, NSS (N = 45) versus radical nephrectomy (RN) (N = 732), in
## BACKGROUND. The treatment of patients with metastatic renal cell carcinoma (RCC) continues to pose a major clinical challenge. Previous studies have suggested that infusional floxuridine (FUDR) has antitumor efficacy and is well tolerated. To the authors knowledge the combination of infusional F